A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Dyslipidemia

Interventions

DRUG

HRS-5632

HRS-5632 Injection

DRUG

Placebo

Sodium chloride injection

Trial Locations (1)

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT06732154 - A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects | Biotech Hunter | Biotech Hunter